Meeting
2020 Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
Authors
Aiwu Ruth He
Georgetown University Hospital, Washington, DC
Aiwu Ruth He , Thomas Yau , Chiun Hsu , Yoon-Koo Kang , Tae-You Kim , Armando Santoro , Bruno Sangro , Ignacio Melero , Masatoshi Kudo , Ming-Mo Hou , Ana Matilla , Francesco Tovoli , Jennifer J. Knox , Bassel F. El-Rayes , Mirelis Acosta-Rivera , Jaclyn Neely , Yun Shen , Marina Tschaika , Anthony B. El-Khoueiry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01658878
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 512)
Abstract #
512
Poster Bd #
B15
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
First Author: Todd S. Crocenzi
Poster
2019 Gastrointestinal Cancers Symposium
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo
Poster
2017 Gastrointestinal Cancers Symposium
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
First Author: Ignacio Melero